SG Americas Securities LLC Cuts Stock Position in CRISPR Therapeutics AG $CRSP

SG Americas Securities LLC cut its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 73.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,737 shares of the company’s stock after selling 10,097 shares during the quarter. SG Americas Securities LLC’s holdings in CRISPR Therapeutics were worth $178,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Mcguire Capital Advisors Inc. purchased a new stake in CRISPR Therapeutics in the fourth quarter worth approximately $25,000. Ramirez Asset Management Inc. bought a new stake in shares of CRISPR Therapeutics in the 4th quarter worth approximately $26,000. Rothschild Investment LLC lifted its holdings in shares of CRISPR Therapeutics by 836.7% in the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after acquiring an additional 502 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. boosted its stake in shares of CRISPR Therapeutics by 196.9% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock valued at $30,000 after purchasing an additional 382 shares in the last quarter. Finally, Strategic Advocates LLC bought a new position in shares of CRISPR Therapeutics during the 3rd quarter valued at $34,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Naimish Patel sold 3,786 shares of CRISPR Therapeutics stock in a transaction on Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the sale, the insider owned 19,357 shares in the company, valued at $1,076,636.34. The trade was a 16.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.30% of the stock is owned by insiders.

CRISPR Therapeutics Trading Down 5.3%

NASDAQ:CRSP traded down $2.99 during mid-day trading on Friday, reaching $53.35. 2,069,985 shares of the company’s stock traded hands, compared to its average volume of 1,550,007. The company has a 50 day moving average price of $53.46 and a 200-day moving average price of $53.17. The firm has a market capitalization of $5.15 billion, a price-to-earnings ratio of -8.58 and a beta of 1.71. The company has a debt-to-equity ratio of 0.32, a current ratio of 17.97 and a quick ratio of 17.96. CRISPR Therapeutics AG has a 12-month low of $44.12 and a 12-month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) earnings per share for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%.The business had revenue of $1.46 million during the quarter. On average, sell-side analysts predict that CRISPR Therapeutics AG will post -4.89 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on CRSP shares. Sanford C. Bernstein lifted their target price on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Wall Street Zen downgraded CRISPR Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, July 5th. Citigroup reissued a “market outperform” rating on shares of CRISPR Therapeutics in a research note on Wednesday, May 27th. Truist Financial upgraded CRISPR Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Piper Sandler restated an “overweight” rating and set a $110.00 price target (up from $105.00) on shares of CRISPR Therapeutics in a research report on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $67.78.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.